secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001625297-25-000076
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Indivior CEO and CFO receive base salary increases effective Jan 1, 2026
------------------------------------------------------------------------

- CEO Joseph Ciaffoni salary increased from $1,050,000 to $1,115,000.
- CFO Ryan Preblick salary increased from $559,000 to $604,000.
- Changes effective January 1, 2026, approved by Board on Dec 12, 2025.
- Based on competitive market review and Compensation Committee recommendation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000076/0001625297-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000076/indv-20251212.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer